Ligand-induced ErbB receptor dimerization.

Structural studies have provided important new insights into how ligand binding promotes homodimerization and activation of the EGF receptor and the other members of the ErbB family of receptor tyrosine kinases. These structures have also suggested possible explanations for the unique properties of ErbB2, which has no known ligand and can cause cell transformation (and tumorigenesis) by simple overexpression. In parallel with these advances, studies of the EGF receptor at the cell surface increasingly argue that the structural studies are missing key mechanistic components. This is particularly evident in the structural prediction that EGF binding linked to receptor dimerization should be positively cooperative, whereas cell-surface EGF-binding studies suggest negative cooperativity. In this review, I summarize studies of ErbB receptor extracellular regions in solution and of intact receptors at the cell surface, and attempt to reconcile the differences suggested by the two approaches. By combining results obtained with receptor 'parts', it is qualitatively possible to explain some models for the properties of the whole receptor. These considerations underline the need to consider the intact ErbB receptors as intact allosterically regulated enzymes, and to combine cellular and structural studies into a complete picture.

[1]  P. Sternberg,et al.  A point mutation in the extracellular domain activates LET-23, the Caenorhabditis elegans epidermal growth factor receptor homolog , 1996, Molecular and cellular biology.

[2]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[3]  G. M. Walton,et al.  Structural analysis of the transmembrane domain of the epidermal growth factor receptor. , 1991, The Journal of biological chemistry.

[4]  John Kuriyan,et al.  An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.

[5]  Michael Kofler,et al.  The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. , 2003, Molecular cell.

[6]  Nathan E Hall,et al.  CR1/CR2 Interactions Modulate the Functions of the Cell Surface Epidermal Growth Factor Receptor* , 2004, Journal of Biological Chemistry.

[7]  A. M. Stanley,et al.  Structure of the extracellular region of HER 2 alone and in complex with the Herceptin Fab , 2022 .

[8]  Peter Klein,et al.  On the nature of low- and high-affinity EGF receptors on living cells. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M. Sliwkowski,et al.  An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. , 2003, Molecular cell.

[10]  T. Wohland,et al.  Investigation of the dimerization of proteins from the epidermal growth factor receptor family by single wavelength fluorescence cross-correlation spectroscopy. , 2007, Biophysical journal.

[11]  F. Maurer,et al.  The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  David Eisenberg,et al.  Heregulin reverses the oligomerization of HER3. , 2000 .

[13]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[14]  P. D. Meyts,et al.  The insulin receptor: a prototype for dimeric, allosteric membrane receptors? , 2008 .

[15]  A. Ullrich,et al.  A chimaeric receptor allows insulin to stimulate tyrosine kinase activity of epidermal growth factor receptor , 1986, Nature.

[16]  G. Carpenter,et al.  Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation , 2007, Proceedings of the National Academy of Sciences.

[17]  Martyn D Winn,et al.  Single-molecule imaging and fluorescence lifetime imaging microscopy show different structures for high- and low-affinity epidermal growth factor receptors in A431 cells. , 2008, Biophysical journal.

[18]  R. Bose,et al.  The ErbB kinase domain: structural perspectives into kinase activation and inhibition. , 2009, Experimental cell research.

[19]  Antony W Burgess,et al.  Epidermal growth factor receptor: mechanisms of activation and signalling. , 2003, Experimental cell research.

[20]  A. Ullrich,et al.  Ligand-induced stimulation of epidermal growth factor receptor mutants with altered transmembrane regions. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Jae-Hoon Kim,et al.  Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains , 2002, Cell.

[22]  Linda J Pike,et al.  Heterogeneity in EGF-binding affinities arises from negative cooperativity in an aggregating system , 2008, Proceedings of the National Academy of Sciences.

[23]  A. Ullrich,et al.  Reconstitution of human epidermal growth factor receptors and its deletion mutants in cultured hamster cells. , 1986, The Journal of biological chemistry.

[24]  M. Sliwkowski,et al.  Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. , 2004, Cancer cell.

[25]  A. Berezov,et al.  Disabling Receptor Ensembles with Rationally Designed Interface Peptidomimetics* , 2002, The Journal of Biological Chemistry.

[26]  Peter Klein,et al.  The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[27]  H. Blau,et al.  A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions , 2006, Proceedings of the National Academy of Sciences.

[28]  Brian Higgins,et al.  Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. , 2002, Cancer cell.

[29]  D. Murray,et al.  An Electrostatic Engine Model for Autoinhibition and Activation of the Epidermal Growth Factor Receptor (EGFR/ErbB) Family , 2005, The Journal of general physiology.

[30]  D. Engelman,et al.  Two EGF molecules contribute additively to stabilization of the EGFR dimer , 1997, The EMBO journal.

[31]  E. Mekada,et al.  Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling. , 2002, Molecular biology of the cell.

[32]  J. Beechem,et al.  Preparation and characterization of Alexa Fluor 594-labeled epidermal growth factor for fluorescence resonance energy transfer studies: application to the epidermal growth factor receptor. , 2004, Analytical biochemistry.

[33]  P. D. Meyts,et al.  The structural basis of insulin and insulin-like growth factor-I receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling , 1994, Diabetologia.

[34]  Ron Bose,et al.  Mechanism of activation and inhibition of the HER4/ErbB4 kinase. , 2008, Structure.

[35]  M. Lemmon,et al.  Extracellular domains drive homo‐ but not hetero‐dimerization of erbB receptors , 2000, The EMBO journal.

[36]  J. Schlessinger,et al.  Allosteric regulation of the epidermal growth factor receptor kinase , 1986, The Journal of cell biology.

[37]  A. Citri,et al.  The deaf and the dumb: the biology of ErbB-2 and ErbB-3. , 2003, Experimental cell research.

[38]  K Lund,et al.  Implications of epidermal growth factor (EGF) induced egf receptor aggregation. , 1992, Biophysical journal.

[39]  N. Hynes,et al.  ErbB receptors: directing key signaling networks throughout life. , 2004, Annual review of pharmacology and toxicology.

[40]  G. Todaro,et al.  Biologically active phorbol esters specifically alter affinity of epidermal growth factor membrane receptors , 1979, Nature.

[41]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[42]  E C Nice,et al.  Stoichiometry, Kinetic and Binding Analysis of the Interaction between Epidermal Growth Factor (EGF) and the Extracellular Domain of the EGF Receptor , 2000, Growth factors.

[43]  M. Sliwkowski,et al.  Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.

[44]  L. Matrisian,et al.  Epidermal growth factor. Ability of tumor promoter to alter its degradation, receptor affinity and receptor number. , 1980, The Journal of biological chemistry.

[45]  I. Lax,et al.  Ligand-binding enhances the affinity of dimerization of the extracellular domain of the epidermal growth factor receptor. , 1997, Journal of biochemistry.

[46]  J. Schlessinger,et al.  Signal transduction by allosteric receptor oligomerization. , 1988, Trends in biochemical sciences.

[47]  T. Hazlett,et al.  Structure and dynamics of the epidermal growth factor receptor C‐terminal phosphorylation domain , 2006, Protein science : a publication of the Protein Society.

[48]  G. Carpenter,et al.  ErbB-4: mechanism of action and biology. , 2003, Experimental cell research.

[49]  Y. Teramura,et al.  Single‐molecule analysis of epidermal growth factor binding on the surface of living cells , 2006, EMBO Journal.

[50]  Joseph Schlessinger,et al.  SH2 and PTB Domains in Tyrosine Kinase Signaling , 2003, Science's STKE.

[51]  J. Sturgis,et al.  A dimerization hierarchy in the transmembrane domains of the HER receptor family. , 2007, Biochemistry.

[52]  R. Kumar,et al.  Ligand-induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly. , 1991, The Journal of biological chemistry.

[53]  J. Schlessinger Autoinhibition Control , 2003, Science.

[54]  M. Lemmon,et al.  ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface , 2004, FEBS letters.

[55]  A. Chantry The kinase domain and membrane localization determine intracellular interactions between epidermal growth factor receptors. , 1995, The Journal of biological chemistry.

[56]  R. Jorissen,et al.  Identification of a determinant of epidermal growth factor receptor ligand-binding specificity using a truncated, high-affinity form of the ectodomain. , 2001, Biochemistry.

[57]  I. Maruyama,et al.  All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells , 2008, Journal of Cell Science.

[58]  Hyun-soo Cho,et al.  Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether , 2002, Science.

[59]  J. Schlessinger,et al.  Epidermal Growth Factor Receptor Dimerization and Activation Require Ligand-Induced Conformational Changes in the Dimer Interface , 2005, Molecular and Cellular Biology.

[60]  Samuel Bouyain,et al.  The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[62]  Edouard C. Nice,et al.  Ligand-induced Dimer-Tetramer Transition during the Activation of the Cell Surface Epidermal Growth Factor Receptor-A Multidimensional Microscopy Analysis* , 2005, Journal of Biological Chemistry.

[63]  N. Mckern,et al.  High affinity insulin binding by soluble insulin receptor extracellular domain fused to a leucine zipper , 2000, FEBS letters.

[64]  M. Lemmon,et al.  Ligand-induced structural transitions in ErbB receptor extracellular domains. , 2007, Structure.

[65]  J. Carlsson,et al.  Binding of epidermal growth factor (EGF) to a cultured human glioma cell line. , 1991, Journal of receptor research.

[66]  P. Jeffrey,et al.  Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. , 2005, Cancer cell.

[67]  P. Sternberg,et al.  Extracellular domain determinants of LET-23 (EGF) receptor tyrosine kinase activity in Caenorhabditis elegans , 2003, Oncogene.

[68]  M. Lemmon,et al.  The Single Transmembrane Domains of ErbB Receptors Self-associate in Cell Membranes* , 2002, The Journal of Biological Chemistry.

[69]  E. Elson,et al.  Oligomerization of the EGF receptor investigated by live cell fluorescence intensity distribution analysis. , 2007, Biophysical journal.

[70]  Y. Yarden,et al.  Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. , 1987, Biochemistry.

[71]  H. Kitano,et al.  A comprehensive pathway map of epidermal growth factor receptor signaling , 2005, Molecular systems biology.

[72]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[73]  Edouard C. Nice,et al.  Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α , 2002, Cell.

[74]  M. Lawrence,et al.  The insulin and EGF receptor structures: new insights into ligand-induced receptor activation. , 2007, Trends in biochemical sciences.

[75]  Colin W. Ward,et al.  The relationship between the L1 and L2 domains of the insulin and epidermal growth factor receptors and leucine-rich repeat modules , 2001, BMC Bioinformatics.

[76]  M. Martin-Fernandez,et al.  Preformed oligomeric epidermal growth factor receptors undergo an ectodomain structure change during signaling. , 2002, Biophysical journal.

[77]  Y. Yarden,et al.  Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. , 1987, Biochemistry.

[78]  Jonathan A. Cooper,et al.  Protein kinase C phosphorylation of the EGF receptor at a threonine residue close to the cytoplasmic face of the plasma membrane , 1984, Nature.

[79]  I. Maruyama,et al.  Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain. , 2001, Journal of molecular biology.

[80]  M. Sliwkowski,et al.  Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). , 1999, Seminars in oncology.

[81]  T. Walz,et al.  Functional and structural stability of the epidermal growth factor receptor in detergent micelles and phospholipid nanodiscs. , 2008, Biochemistry.

[82]  M. Sliwkowski,et al.  Identification of a Region within the ErbB2/HER2 Intracellular Domain That Is Necessary for Ligand-independent Association* , 2002, The Journal of Biological Chemistry.

[83]  Toshio Yanagida,et al.  Single-molecule imaging of EGFR signalling on the surface of living cells , 2000, Nature Cell Biology.

[84]  D. Davies,et al.  A unified model of c-erbB receptor homo- and heterodimerisation. , 1998, Biochimica et biophysica acta.

[85]  S. Gabriel,et al.  Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain , 2006, PLoS medicine.

[86]  D. Gross,et al.  Thermodynamic mixing of molecular states of the epidermal growth factor receptor modulates macroscopic ligand binding affinity. , 2000, The Biochemical journal.

[87]  D. Vlachos,et al.  Heterogeneities in EGF receptor density at the cell surface can lead to concave up scatchard plot of EGF binding , 2005, FEBS letters.

[88]  K. Ferguson,et al.  Structure-based view of epidermal growth factor receptor regulation. , 2008, Annual review of biophysics.

[89]  Joseph Schlessinger,et al.  Ligand-Induced, Receptor-Mediated Dimerization and Activation of EGF Receptor , 2002, Cell.

[90]  N. Mckern,et al.  The three dimensional structure of the type I insulin-like growth factor receptor , 2001, Molecular pathology : MP.

[91]  D. Steiner,et al.  Fusion of Insulin Receptor Ectodomains to Immunoglobulin Constant Domains Reproduces High-affinity Insulin Binding in Vitro* , 1996, The Journal of Biological Chemistry.

[92]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[93]  A. Ullrich,et al.  High-affinity epidermal growth factor binding is specifically reduced by a monoclonal antibody, and appears necessary for early responses , 1990, The Journal of cell biology.

[94]  T. Hunter,et al.  Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors , 1989, The Journal of cell biology.

[95]  Peter Klein,et al.  A structure-based model for ligand binding and dimerization of EGF receptors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[96]  Hyun-soo Cho,et al.  EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. , 2003, Molecular cell.

[97]  T M Jovin,et al.  Oligomerization of epidermal growth factor receptors on A431 cells studied by time-resolved fluorescence imaging microscopy. A stereochemical model for tyrosine kinase receptor activation , 1995, The Journal of cell biology.

[98]  T. Arakawa,et al.  Binding of Neu Differentiation Factor with the Extracellular Domain of Her2 and Her3 (*) , 1995, The Journal of Biological Chemistry.